Expand MAIA Menu
MAIA MENU

MAIA Latest Press Releases

-- April 16, 2026 --

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer Globe Newswire 9:20 AM

-- April 8, 2026 --

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy Globe Newswire 9:00 AM

-- March 31, 2026 --

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer Globe Newswire 9:15 AM

-- March 27, 2026 --

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 8:00 AM

-- March 5, 2026 --

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 4:00 PM

-- March 4, 2026 --

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock Globe Newswire 4:00 PM

-- March 2, 2026 --

MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock Globe Newswire 10:45 PM
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 5:00 PM

-- February 24, 2026 --

MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market Globe Newswire 8:45 AM

-- January 20, 2026 --

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum Globe Newswire 10:15 AM
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 8:00 AM

-- December 24, 2025 --

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings Globe Newswire 8:01 AM

-- December 16, 2025 --

MAIA Biotechnology Announces $1.51 Million Private Placement Globe Newswire 4:15 PM

-- December 11, 2025 --

MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates Globe Newswire 1:00 PM
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer Globe Newswire 9:00 AM
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential Globe Newswire 8:00 AM

-- December 10, 2025 --

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach Globe Newswire 2:00 PM

-- December 1, 2025 --

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors Globe Newswire 9:17 AM

-- November 21, 2025 --

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 Globe Newswire 9:01 AM

-- November 20, 2025 --

MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania's 2025 Smart Diaspora Conference on Oncology Research and Innovation Globe Newswire 8:47 AM
Market Data Delayed 15 Minutes